^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

WT1 overexpression

i
Other names: WT1, WT1 Transcription Factor, Wilms Tumor Protein, Wilms Tumor 1, WT33, NPHS4, WIT-2, AWT1, WAGR, GUD
Entrez ID:
1m
Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia. (PubMed, Front Oncol)
WT1MRD response post-intensification I serves as an independent prognostic factor for survival in pediatric AML. Integration of WT1 and MFC-based MRD results enhances the reliability of MRD-based prognostic stratification, particularly in patients lacking specific leukemic markers, thereby influencing treatment strategies.
Journal
|
RUNX1 (RUNX Family Transcription Factor 1) • WT1 (WT1 Transcription Factor) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)
|
WT1 overexpression
2ms
Overexpression of WT1 in all molecular subtypes of breast cancer and its impact on survival: exploring oncogenic and tumor suppressor roles of distinct WT1 isoforms. (PubMed, Mol Biol Rep)
Interestingly, this overexpression was observed in all molecular subtypes of invasive breast cancer, underscoring the significance of WT1 as a potential target in all these subtypes. The observed WT1 down-expression in a few cases of invasive breast cancer, associated with better survival outcomes, may correspond to the down-regulation of a particular WT1-KTS (-) isoform: the WT1 A isoform (EX5-/KTS-). The co-expression of this WT1 oncogenic isoform with a regulated WT1- tumor suppressor isoform, such as the major WT1 F isoform (EX5-/KTS +), could also explain such survival outcomes. Due to its capacity to adopt dual roles, it becomes imperative to conduct individual molecular expression profiling of the WT1 gene. Such an approach holds great promise in the development of personalized treatment strategies for breast cancer.
Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 overexpression
4ms
Up-regulation of lncRNA WT1-AS ameliorates Aβ-stimulated neuronal injury through modulation of miR-186-5p/CCND2 axis in Alzheimer's disease. (PubMed, Cell Mol Biol (Noisy-le-grand))
Furthermore, CCND2 elevation partially offsets the impacts of miR-186-5p elevation on Aβ1-42-stimulated cell proliferation as well as apoptosis mediated with WT1-AS up-regulation. Our results indicated that up-regulation of lncRNA WT1-AS ameliorated Aβ-stimulated neuronal damage through modulating miR-186-5p/CCND2 axis, offering a novel direction for AD therapy.
Journal
|
WT1 (WT1 Transcription Factor) • CCND2 (Cyclin D2) • MIR186 (MicroRNA 186)
|
WT1 overexpression • miR-186 overexpression
5ms
Prognostic significance of Wilms' tumor gene 1 expression in children with B-cell precursor acute lymphoblastic leukemia. (PubMed, Front Oncol)
In B-other patients, WT1 overexpression at diagnosis predicted an inferior prognosis. The WT1 gene may serve as a biomarker for monitoring residual disease in the B-other population, especially in children in the standard-risk group.
Journal
|
KMT2A (Lysine Methyltransferase 2A) • WT1 (WT1 Transcription Factor)
|
KMT2A rearrangement • MLL rearrangement • WT1 overexpression
5ms
Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning. (PubMed, Eur J Haematol)
These results confirm that qPCR targeting NPM1 mutations or fusion transcripts are superior in MRD testing. In the absence of such targets, ddPCR is a promising alternative demonstrating (a) high applicability, (b) high sensitivity, and (c) zero false positive MRD relapses in non-relapsing patients.
Journal
|
NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • WT1 (WT1 Transcription Factor)
|
NPM1 mutation • DNMT3A mutation • ASXL1 mutation • TET2 mutation • WT1 overexpression
5ms
Wilms' tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP. (PubMed, PLoS Pathog)
Finally, we show that ESK-1, a T cell receptor-like monoclonal antibody that recognizes WT1 peptides presented on MHC HLA-A0201, shows increased binding to endothelial cells after KSHV infection or induction of vFLIP expression. We propose that oncogenic isoforms of WT1 are upregulated by KSHV to promote tumorigenesis and that immunotherapy directed against WT1 may be an approach for KS treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • WT1 (WT1 Transcription Factor)
|
WT1 overexpression
6ms
Clinical significance of WT1 in the evaluation of therapeutic effect and prognosis of non-M3 acute myeloid leukemia. (PubMed, Cancer Biol Ther)
Idarubicin + Cytarabine (IA) regimen could reduce the expression level of WT1 after treatment, and Allo-HSCT played an important role in improving the prognosis of patients with WT1 high expression and patients with WT1 negativity. Different clinical background should be taken into consideration when we judge the prognosis and therapeutic effect of patients with WT1 mutations. In addition, WT1 may be an optional MRD marker, which needs regular monitoring.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • WT1 (WT1 Transcription Factor)
|
FLT3-ITD mutation • NPM1 mutation • WT1 mutation • WT1 overexpression
|
cytarabine • idarubicin hydrochloride
8ms
Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features (ASH 2023)
A total of 27 (7.6%) MDS/CMML patients with trisomy 8 (21 with trisomy 8 at baseline) were found to have a bona fide autoimmune disease, including autoimmune uveitis/scleritis (n=3), (rheumatoid and psoriatic), polyarteritis nodosa, giant cell arteritis with polymyalgia rheumatica, autoimmune sclerosing pancreatitis, immune hemolytic anemia, synovitis, and Grave's disease. Conclusions MDS/CMML with trisomy 8 showed unique clinicopathologic characteristics compared to MDS-NK: higher baseline BM blasts, higher representation of "Very High" IPSS-R risk categories with characteristic mutational signatures and a variety of underlying autoimmune diseases.
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CD8 (cluster of differentiation 8) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • SRSF2 (Serine and arginine rich splicing factor 2) • WT1 (WT1 Transcription Factor) • STAG2 (Stromal Antigen 2)
|
KRAS mutation • Chr del(11q) • ASXL1 mutation • CD8 positive • Chr del(5q) • STAG2 mutation • WT1 overexpression
9ms
A Nucleus-Targeting WT1 Antagonistic Peptide Encapsulated in Polymeric Nanomicelles Combats Refractory Chronic Myeloid Leukemia. (PubMed, Pharmaceutics)
Moreover, subcutaneous injections of M-WIP2W were observed to significantly enhance intra-tumoral accumulation and to effectively inhibit tumor growth. Thus, WIP2W stands out as a potent and selective WT1 inhibitor, and the M-WIP2W nanoformulation appears promising for the therapeutic treatment of refractory CML as well as other WT1-overexpressing malignant cancers.
Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 overexpression
9ms
Wilms' tumor gene 1 in hematological malignancies: friend or foe? (PubMed, Hematology)
Many researchers were interested in developing WT1 targeting therapy. In this review, we summarized biological and pathological functions, correlation with other genes and clinical features, prognosis value and targeting therapy of WT1 in hematological features.
Review • Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 mutation • WT1 overexpression
11ms
Understanding WT1 Alterations and Expression Profiles in Hematological Malignancies. (PubMed, Cancers (Basel))
Functionally, inhibition of the nonsense-mediated mRNA decay machinery revealed that under natural conditions, the mutated WT1 alleles go through a robust degradation. These results offer new insights and model systems regarding the characteristics of WT1 in leukemia and lymphoma.
Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 mutation • WT1 overexpression
1year
Primary testicular lymphoma demonstrates overexpression of the Wilms tumor 1 gene and different mRNA and miRNA expression profiles compared to nodal diffuse large B-cell lymphoma. (PubMed, Hematol Oncol)
This research revealed higher WT1 expression in PTL relative to nodal DLBCL, suggesting that a specific miRNA subset may target WT1 expression and impact the PI3k/Akt pathway in PTL. Further investigation is needed to explore WT1's biological role in PTL and its potential as a therapeutic target.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule) • WT1 (WT1 Transcription Factor) • GAS1 (Growth Arrest Specific 1) • LAMC2 (Laminin subunit gamma 2) • MIR199B (MicroRNA 199b) • MIR132 (MicroRNA 132) • MIR16 (MicroRNA 16) • MIR199A (MicroRNA 199a) • MIR27B (MicroRNA 27b) • MIR361 (MicroRNA 361) • MIR128 (MicroRNA 128) • MMP7 (Matrix metallopeptidase 7) • THBS4 (Thrombospondin 4)
|
MYD88 mutation • CD79B mutation • WT1 overexpression • GAS1 expression
1year
REAL-WORLD RESEARCH OF CLINICAL AND HEMATOLOGIC NEOPLASMS RELATED GENETIC MUTATIONS IN 275 POLYCYTHEMIA VERA PATIENTS (EHA 2023)
PV patients with different JAK2 gene mutational status had various clinical characteristics. JAK2 V617F allele burden was positively correlated with the age of onset, leukocyte counts and lactate dehydrogenase values. WT1 gene is overexpressed in PV, and the expression level of WT1 was positively correlated with JAK2V617F allele burden.
Clinical • Real-world evidence • Real-world
|
JAK2 (Janus kinase 2) • TET2 (Tet Methylcytosine Dioxygenase 2) • WT1 (WT1 Transcription Factor)
|
TET2 mutation • JAK2 V617F • JAK2 mutation • WT1 mutation • WT1 overexpression
1year
MEASURABLE RESIDUAL DISEASE DETECTED BY WT1 IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN CHILDREN WITH ACUTE MYELOID LEUKEMIA (EHA 2023)
MRD assessment by WT1 can be used as a sensitive tool for prediction of the clinical outcome in pediatric patients with AML. Incorporation of MRD results by both WT1 and MFC enhanced the reliability of MRD-based prognostic stratification especially in patients without specific markers to be followed and hence influence the treatment strategies.
Clinical
|
WT1 (WT1 Transcription Factor)
|
WT1 overexpression
1year
The Distribution and Significance of Activated T Cells and Lymphocyte Subsets in Myelodysplastic Syndrome (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
In MDS patients, the proportion of CD3T and CD4T lymphocytes decreased, and the proportion of activated T cells increased, indicating that the differentiation type of MDS is more primitive and the prognosis is worse.
Journal
|
WT1 (WT1 Transcription Factor) • CD34 (CD34 molecule)
|
WT1 overexpression
1year
Wilms' tumor 1 expression combined with genetic mutations for prognostic assessment in MDS. (PubMed, Leuk Lymphoma)
In multivariate analysis, higher WT1 expression was a risk factors for OS in EB patients without TP53 mutations. Overall, WT1 expression was useful to predict prognosis for MDS and its prognostic role was impacted by some gene mutations.
Journal
|
TP53 (Tumor protein P53) • NPM1 (Nucleophosmin 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • WT1 (WT1 Transcription Factor)
|
TP53 mutation • NPM1 mutation • TET2 mutation • SRSF2 mutation • TP53 expression • WT1 mutation • WT1 overexpression
1year
The roles and molecular mechanisms of long non-coding RNA WT1-AS in the maintenance and development of gastric cancer stem cells. (PubMed, Heliyon)
In conclusion, WT1-AS weakened the stem cell-like behaviors and characteristics of GCSCs in vitro and in vivo by down-regulating WT1. Investigations into the molecular mechanisms underlying the complex phenotypes of GCSCs might contribute to the better management of gastric cancer.
Journal • Cancer stem
|
WT1 (WT1 Transcription Factor) • PHGDH (Phosphoglycerate Dehydrogenase) • XBP1 (X-box-binding protein 1)
|
WT1 overexpression
|
5-fluorouracil
1year
Therapeutic Effects of WT1 Silencing via Respiratory Administration of Neutral DOPC Liposomal-siRNA in a Lung Metastasis Melanoma Murine Model. (PubMed, Noncoding RNA)
In the survival study, L-WT1 treatment could significantly delay the death of the animals. This work demonstrates the efficacy of the L-siRNA respiratory administration as a novel therapy to reduce pulmonary tumors and to increase survivability by silencing specific cancer oncogenes as WT1.
Preclinical • Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 overexpression
over1year
Therapeutic effects of WT1 silencing by respiratory administration of liposomal siRNA in a melanoma murine model (AACR 2023)
This work demonstrates the efficacy of the neutral DOPC liposomal-siRNA delivery system by respiratory administration as a novel therapy to reduce the malignancy of pulmonary tumors and to increase survivability by silencing specific cancer biomarkers as WT1.
Preclinical
|
WT1 (WT1 Transcription Factor)
|
WT1 overexpression
over1year
Molecular mechanism of Wilms' tumor (Wt1) (+/-KTS) variants promoting proliferation and migration of ovarian epithelial cells by bioinformatics analysis. (PubMed, J Ovarian Res)
Finally, we found that the regulation of Wt1 (+/-KTS) variants on the proliferation and migration of HOSEpiC may act through different genes and signaling pathways and screened out key genes and differentially regulated genes that regulate the malignant transformation of ovarian epithelial cells. The implementation of this study will provide new clues for the early diagnosis and precise treatment of OC.
Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 overexpression
over1year
High WT1 expression predicted induction chemotherapy failure in acute myeloid leukemia patients with non-favorable cytogenetic risk. (PubMed, Clin Exp Med)
Moreover, WT1-H patients had a significantly lower RFS rate than WT1-L patients within both FAB-M5 and KMT2A rearrangement subgroups (P = 0.010 and 0.028), whereas WT1 had no impact on RFS within other subgroups mentioned above (all P > 0.05). Therefore, high WT1 expression at diagnosis independently predicted induction chemotherapy failure in AML patients with non-favorable cytogenetic risk, and it was related to relapse just within FAB-M5 and KMT2A rearrangement subgroups.
Journal
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • WT1 (WT1 Transcription Factor) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
TP53 mutation • FLT3-ITD mutation • NPM1 mutation • KMT2A rearrangement • MLL rearrangement • CEBPA mutation • WT1 overexpression • KMT2A-PTD
over1year
Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation. (PubMed, Molecules)
shikonin can down-regulate the WT1 protein level for leukemia differentiation therapy, and 2. the interaction between WT1 and CD34 proteins may be responsible for granulocyte/monocyte immaturity in HL-60 cells.
Journal
|
WT1 (WT1 Transcription Factor) • CD34 (CD34 molecule) • ITGAM (Integrin, alpha M)
|
WT1 overexpression
over1year
Biomarker Expression Profiling in Cervix Carcinoma Biopsies Unravels WT1 as a Target of Artesunate. (PubMed, Cancer Genomics Proteomics)
WT1 may represent a novel target of ART in cancer cells that contribute to the response of tumor cells to this drug.
Journal
|
CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor) • GSTP1 (Glutathione S-transferase pi 1) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
|
WT1 overexpression
over1year
Persistence of Mutations in Complete Remission Including DNMT3A, TET2 and ASXL1 Mutations Is Associated with Worse Prognosis in Patients with Acute Myeloid Leukemia Treated in ALFA 0702 Study (ASH 2022)
In the homogeneously treated ALFA-0702 population, MRD-NGS positivity after the first induction course predicts shorter LFS and OS independently of ELN17 risk stratification. Detection of a higher number of mutations in CR is associated with a worse prognosis. Contrary to previous studies accruing older patients treated less intensively persistence of DTA mutations has similar prognostic relevance than non-DTA mutations.
Clinical
|
NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • WT1 (WT1 Transcription Factor)
|
NPM1 mutation • DNMT3A mutation • ASXL1 mutation • TET2 mutation • WT1 overexpression • NPM1 expression • WT1 positive
almost2years
lncRNA WT1-AS attenuates hypoxia/ischemia-induced neuronal injury during cerebral ischemic stroke via miR-186-5p/XIAP axis. (PubMed, Open Med (Wars))
Similarly, transfection with the miR-186-5p inhibitor reduced OGD-induced neuronal damage by upregulating XIAP expression. In conclusion, lncRNA WT1-AS attenuates hypoxia/ischemia-induced neuronal injury in cerebral ischemic stroke through the miR-186-5p/XIAP axis.
Journal
|
WT1 (WT1 Transcription Factor) • CASP3 (Caspase 3) • XIAP (X-Linked Inhibitor Of Apoptosis)
|
WT1 overexpression
almost2years
WT1 Inhibits Human Renal Carcinoma Cell Proliferation and Induces G2/M Arrest by Upregulating IL-24 Expression. (PubMed, Biomed Res Int)
Our results demonstrated that the overexpression of WT1 upregulates IL-24, leading to G2/M checkpoint arrest to reduce proliferation. These results indicate that regulation of IL-24 by WT1 inhibits proliferation and may represent a potential target for treating renal carcinoma.
Journal
|
WT1 (WT1 Transcription Factor) • TXNIP (Thioredoxin Interacting Protein)
|
WT1 overexpression
almost2years
Novel ATXN1/ATXN1L::NUTM2A fusions identified in aggressive infant sarcomas with gene expression and methylation patterns similar to CIC-rearranged sarcoma. (PubMed, Acta Neuropathol Commun)
These three cases with novel ATXN1/ATXN1L-associated fusions and features of CIC-rearranged sarcomas may further expand the scope of "CIC-rearranged" sarcomas to include non-CIC rearrangements. Additional cases are needed to demonstrate if ATXN1/ATXN1L-NUTM2A fusions are associated with younger age and more aggressive diseases.
Journal
|
WT1 (WT1 Transcription Factor) • ETV1 (ETS Variant Transcription Factor 1) • ATXN1L (ataxin 1 like) • NUTM2A (NUT Family Member 2A) • ETV4 (ETS Variant Transcription Factor 4)
|
WT1 overexpression
almost2years
The Role of Wilms' Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia. (PubMed, J Clin Med)
In addition, we provided some practical considerations on how to properly use WT1 expression as an MRD marker, considering its strengths and weaknesses. In order to achieve the best sensitivity and specificity, it is recommended to refer to the standardized method of European LeukemiaNet and its defined threshold (250 WT1 copies/10 Abelson (ABL) on Bone Marrow-BM and 50 WT1 copies/10 ABL on Peripheral Blood-PB), which has been validated in a large and multicenter cohort of patients and normal controls.
Review • Journal • Minimal residual disease
|
WT1 (WT1 Transcription Factor)
|
WT1 overexpression
almost2years
Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study. (PubMed, J Cancer Res Clin Oncol)
The results of this study indicated that a comprehensive evaluation of BM features, clinical phenotypes, haematologic parameters, and molecular profiles is needed for the accurate diagnosis and treatment of ET, pre-PMF, and overt PMF patients.
Retrospective data • Journal • Next-generation sequencing
|
TP53 (Tumor protein P53) • ABL1 (ABL proto-oncogene 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • WT1 (WT1 Transcription Factor) • EP300 (E1A binding protein p300)
|
TP53 mutation • ASXL1 mutation • LDH-L • WT1 overexpression • EP300 mutation
2years
ANALYSIS REVEALS CANCER-ASSOCIATED GENE MUTATIONS IN CHRONIC MYELOID LEUKEMIA PATIENTS :A CHINESE MONOCENTRIC RETROSPECTIVE STUDY (EHA 2022)
The treatment effect of CML patients with NOTCH3, RELN and ASXL1 mutations and more than two gene mutations is poor. CML patients with high expression of WT1 at diagnosis have poor therapeutic effect in the early stage.
Retrospective data
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2C (Lysine Methyltransferase 2C) • WT1 (WT1 Transcription Factor) • NOTCH3 (Notch Receptor 3)
|
ASXL1 mutation • KMT2C mutation • WT1 overexpression • MLL3 mutation
2years
CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. (PubMed, Sci Transl Med)
A unique WT1-specific TCR showed antigen-specific responses and efficiently killed AML blasts, acute lymphoblastic leukemia blasts, and glioblastoma cells in vitro and in vivo in the absence of off-tumor toxicity. T cells engineered to express this receptor are being advanced into clinical development for AML immunotherapy and represent a candidate therapy for other WT1-expressing tumors.
Journal • IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • WT1 (WT1 Transcription Factor)
|
HLA-A*02 • WT1 overexpression
2years
WT1 Gene Mutations, rs16754 Variant, and WT1 Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients. (PubMed, J Clin Med)
The difference in WT1 expression between patients with normal and abnormal karyotype was statistically insignificant; (4) WT1 gene expression and its rs16754 variant at diagnosis did not affect AML outcome. WT1 mutation may affect RFS in AML.
Journal
|
NPM1 (Nucleophosmin 1) • WT1 (WT1 Transcription Factor) • CD34 (CD34 molecule) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
NPM1 mutation • CEBPA mutation • WT1 mutation • WT1 overexpression
2years
Detection of RAS gene mutation and its clinical significance in children with acute lymphoblastic leukemia. (PubMed, Zhongguo Dang Dai Er Ke Za Zhi)
RAS gene mutation is commonly observed in children with B-lineage acute lymphoblastic leukemia and may have an adverse effect on prognosis.
Retrospective data • Journal
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • WT1 (WT1 Transcription Factor)
|
KRAS mutation • NRAS mutation • WT1 mutation • WT1 overexpression
over2years
Serum WT1-271 IgM antibody as a novel diagnostic marker for Gastric Cancer. (PubMed, Mol Clin Oncol)
Serum WT1-271 IgM antibody levels were not significantly associated with clinicopathological factors but were associated with unfavorable prognosis. Serum WT1-271 IgM antibody levels could serve as a diagnostic biomarker in patients with gastric cancer.
Journal • IO biomarker
|
WT1 (WT1 Transcription Factor)
|
WT1 overexpression
over2years
Donor-Derived Leukemia in a Recipient of Double-Unit Cord Blood Transplantation for Acute Myeloid Leukemia: A Case Study and Literature Review. (PubMed, Oncol Ther)
Although cases of DDL occurring after umbilical CBT have already been reported, very few cases have been described arising after double-unit CBT. DDL cases following CBT previously described in the literature have been reviewed.
Review • Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 overexpression
over2years
Optimal time-points for detecting expression levels of BAALC, EVI1, and WT1 genes in patients with acute myeloid leukemia: a meta-analysis. (PubMed, Hematology)
Post-consolidation WT1 overexpression consistently indicated an increased risk of relapse, while the combined HR for RFS was statistically insignificant (SHR = 4.22). These findings confirm the application of BAALC and EVI1 at diagnosis, WT1 after induction chemotherapy in AML patients throughout conventional chemotherapy.
Retrospective data • Journal
|
WT1 (WT1 Transcription Factor) • BAALC (BAALC Binder Of MAP3K1 And KLF4)
|
WT1 overexpression